Cardiol Therapeutics Inc. (TSE:CRDL - Get Free Report) reached a new 52-week low during trading on Tuesday . The company traded as low as C$1.48 and last traded at C$1.57, with a volume of 60153 shares. The stock had previously closed at C$1.57.
Cardiol Therapeutics Stock Performance
The stock has a market capitalization of C$139.40 million, a PE ratio of -3.30 and a beta of 0.70. The business has a 50 day moving average price of C$1.84 and a 200 day moving average price of C$2.28. The company has a debt-to-equity ratio of 1.59, a current ratio of 2.49 and a quick ratio of 6.84.
Insider Transactions at Cardiol Therapeutics
In other Cardiol Therapeutics news, Senior Officer Andrew Warwick Hamer acquired 18,900 shares of the company's stock in a transaction that occurred on Thursday, December 19th. The shares were bought at an average cost of C$1.88 per share, with a total value of C$35,606.69. Also, Senior Officer Guillermo Torre bought 17,240 shares of the stock in a transaction on Thursday, December 26th. The stock was purchased at an average cost of C$1.81 per share, for a total transaction of C$31,277.77. Over the last three months, insiders have purchased 86,140 shares of company stock valued at $161,456. Insiders own 4.57% of the company's stock.
Cardiol Therapeutics Company Profile
(
Get Free Report)
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
See Also
Before you consider Cardiol Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.
While Cardiol Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
